Citation Impact
Citing Papers
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2017 Standout
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
Parenteral Anticoagulants
2008
Parenteral Anticoagulants
2012 Standout
The natural history and epidemiology of venous thrombosis
1994
A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis
1998 Standout
Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin
2008
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study
2000
Low Molecular Weight Heparin
1997
Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
2000 Standout
Elevation of Hepatic Transaminases after Enoxaparin Use: Case Report and Review of Unfractionated and Low‐Molecular‐Weight Heparin‐Induced Hepatotoxicity
2001
The use of low molecular weight heparin in pediatric patients: A prospective cohort study
2000
Antithrombotic Therapy for VTE Disease
2016 Standout
Low-Molecular-Weight Heparin (Fragmin) During Instability in Coronary Artery Disease (FRISC)
1997
Risk factors for bleeding in major abdominal surgery using heparin thromboprophylaxis
1997
Therapy of venous thromboembolism in patients with brain metastases
1994
Prevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty
2005
Temporal Aspects of Heparin-Induced Thrombocytopenia
2001 Standout
Prevention of VTE in Nonsurgical Patients
2012 Standout
Once versus twice daily LMWH for the initial treatment of venous thromboembolism
2002
Modern Management of Prosthetic Valve Anticoagulation
1998
Antithrombotic Therapy for VTE Disease
2012 Standout
Low-molecular-weight heparin in pediatric patients with thrombotic disease: A dose finding study
1996
Monitoring of low-molecular-weight heparins in cardiovascular disease
1998
Heparin and Low-Molecular-Weight Heparin
2004
A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Acute Pulmonary Embolism
1997
A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein Thrombosis
1996
Low-Molecular-Weight Heparin for the Treatment of Acute Ischemic Stroke
1995
Diabetes and Atherosclerosis
2002 Standout
Prophylaxis of Thromboembolism in Spinal Cord-Injured Patients
1992
Prevention of VTE in Nonorthopedic Surgical Patients
2012 Standout
Prevention of Venous Thromboembolism
2004 Standout
Heparin and Low-Molecular-Weight Heparin
1998
How were new medicines discovered?
2011 Standout
The Hazards of Scoring the Quality of Clinical Trials for Meta-analysis
1999 Standout
Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment
2002
Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
2003 Standout
Intravenous heparin dosing
1993
Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin
1995 Standout
Sickle-cell disease
2010 Standout
Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism
2005
Development of a Novel Recombinant Serpin with Potential Antithrombotic Properties
1995
Comparison of Enoxaparin and Warfarin for the Prevention of Venous Thromboembolic Disease After Total Hip Arthroplasty. Evaluation During Hospitalization and Three Months After Discharge*
1999
Prevention of Venous Thromboembolism
2008 Standout
Use of Low Molecular Weight Heparin in Preventing Thromboembolism in Trauma Patients
1996
Subacute occlusion, bleeding complications, hospital stay and restenosis after Palmaz-Schatz coronary stenting under a new antithrombotic regimen
1996
Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
1996
Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes
2002
A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease
1997 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
2001 Standout
The TIMI Risk Score for Unstable Angina/Non–ST Elevation MI
2000 Standout
Long-term Treatment of Deep Venous Thrombosis with a Low Molecular Weight Heparin (Tinzaparin): A Prospective Randomized Trial
2005
Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction
1996
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
2011 Standout
Complications of Femoral and Subclavian Venous Catheterization in Critically Ill Patients<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
2001 Standout
ENOXAPARIN FOR THROMBOEMBOLISM PROPHYLAXIS IN SPINAL INJURY
1996
Randomized Trial of Low Molecular Weight Heparin (Dalteparin) in Prevention of Left Ventricular Thrombus Formation and Arterial Embolism After Acute Anterior Myocardial Infarction: The Fragmin in Acute Myocardial Infarction (FRAMI) Study 11This study was supported by grants from the Norwegian Council on Cardiovascular Diseases, Oslo, Norway and Pharmacia AB, Stockholm, Sweden.
1997
Thrombosis of the Cerebral Veins and Sinuses
2005 Standout
Clinical Outcome and Cost of Hospital vs Home Treatment of Proximal Deep Vein Thrombosis With a Low-Molecular-Weight Heparin
2000
Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
1992
Guidelines for the Early Management of Adults With Ischemic Stroke
2007 Standout
Impact of the patient population on the risk for heparin-induced thrombocytopenia
2000 Standout
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Serpin Structure, Mechanism, and Function
2002 Standout
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
2002 Standout
Antibodies Against the Fibrin β-Chain Amino-Terminus Detect Active Canine Venous Thrombi
1997
Comparison of Low-Molecular-Weight Heparin With Unfractionated Heparin Acutely and With Placebo for 6 Weeks in the Management of Unstable Coronary Artery Disease
1997
Low Molecular Weight Heparin
1997
The Effect of Dietary ω-3 Fatty Acids on Coronary Atherosclerosis
1999 Standout
Heparin protects cathepsin G against inhibition by protein proteinase inhibitors.
1994
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
Low Molecular Weight Heparin versus Acenocoumarol in the Secondary Prophylaxis of Deep Vein Thrombosis
1999
Diagnosis and Management of Cerebral Venous Thrombosis
2011 Standout
Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease
2015
Incidence of Recurrent Thromboembolic and Bleeding Complications Among Patients With Venous Thromboembolism in Relation to Both Malignancy and Achieved International Normalized Ratio: A Retrospective Analysis
2000
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Fish Oils and Low-Molecular-Weight Heparin for the Reduction of Restenosis After Percutaneous Transluminal Coronary Angioplasty
1996
The Epidemiology of Venous Thromboembolism
2003 Standout
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2017 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Low-molecular-weight heparin in the management of Tyrousseau's syndrome
1997
Low-Molecular-Weight Heparins
1997 Standout
Managing anticoagulant and antiplatelet drugs in patients who are receiving neuraxial anesthesia and epidural analgesia: a practical guide for clinicians
2006
The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke
1997 Standout
Recent Advances in Venous Thromboembolic Prophylaxis During and After Total Hip Replacement
2000
Management of Deep Vein Thrombosis and Pulmonary Embolism
1996
Comparison of Unfractionated Versus Low Molecular Weight Heparin for Deep Vein Thrombosis Prophylaxis During Breast and Pelvic Cancer Surgery: Efficacy, Safety, and Follow-up
1998
Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS)
2004
Correlation of Antifactor Xa Concentrations with Renal Function in Patients on Enoxaparin
2003
Venous thrombosis: a multicausal disease
1999 Standout
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism
2004
Functions of Cell Surface Heparan Sulfate Proteoglycans
1999 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease
2002 Standout
Prevention of Deep Vein Thrombosis after Hip Replacement
1999
Low‐Molecular‐Weight Heparin versus Warfarin for Prevention of Recurrent Venous Thromboembolism: A Randomized Trial
1996
Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis
2005 Standout
Works of MN Levine being referenced
Treatment of Thrombotic Disorders in Cancer Patients
1997
Low molecular weight heparin
1992